Similar articles

• Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

  Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A. Haller H, et al. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6. J Hypertens. 2006. PMID: 16508590 Clinical Trial.
• Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

  Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Haller H, et al. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994. N Engl J Med. 2011. PMID: 21388309 Clinical Trial.
• Predictors for the development of microalbuminuria and interaction with renal function.

  Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H. Chatzikyrkou C, et al. J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491. J Hypertens. 2017. PMID: 29035939
• Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

  Croom KF, Curran MP, Goa KL, Perry CM. Croom KF, et al. Drugs. 2004;64(9):999-1028. doi: 10.2165/00003495-200464090-00011. Drugs. 2004. PMID: 15101793 Review.
• The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.

  Lewis EJ. Lewis EJ. Am J Hypertens. 2002 Oct;15(10 Pt 2):123S-128S. doi: 10.1016/s0895-7061(02)03007-8. Am J Hypertens. 2002. PMID: 12383593 Review.